Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study

Objective: Chronic migraine (CM) is a significant public health problem that affects 2.2% of the global population. Onabotulinumtoxin A (OnabotA) is a safe and effective prophylactic treatment for patients with CM. The standard injection interval for OnabotA is 12 weeks. Nevertheless, some patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Montolio, Joana, Navarro-Pérez, María Pilar, Almeida-Zurita, Monserrath, Santos-Lasaosa, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455650/
https://www.ncbi.nlm.nih.gov/pubmed/37629402
http://dx.doi.org/10.3390/jcm12165360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455650/
https://www.ncbi.nlm.nih.gov/pubmed/37629402
http://dx.doi.org/10.3390/jcm12165360

Ejemplares similares